New York, USA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Gastroparesis Market Poised for Extraordinary Growth at a 21.9% CAGR in the US by 2034 Due to the Launch of Novel MoAs Such as NK-1R Antagonists, 5-HT4 ...

MILAN — Antidepressants escitalopram and duloxetine have been shown to improve verbal memory in moderate to severe depression, a clinical effect linked to changes in serotonin 4 (5-HT4) receptor ...

The company states: “Silo Pharma (SILO) announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA ...

$452.5 million in total milestone payments $2.5 million in near-term payments Double-digit royalties on future net product sales 3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 ...

Several 5-HT4 receptor (5-HT4R) agonists are approved for treating chronic idiopathic constipation (CIC) by stimulating gastrointestinal (GI) motility. Traditional 5-HT4R agonists act systemically, ...

Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...

First Wave BioPharma Inc (NASDAQ:FWBI) announced an agreement with Sanofi SA (NASDAQ:SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop ...

NEW YORK (Reuters Health) - Scientists from France have found that anorexia and the highly addicting club-drug ecstasy activate some of the same brain pathways, a finding that may help explain the ...

Diabetic Gastroparesis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market ...